Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Non-Current Assets (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Other Non-Current Assets for 4 consecutive years, with $881000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets fell 73.76% year-over-year to $881000.0, compared with a TTM value of $881000.0 through Sep 2025, down 73.76%, and an annual FY2024 reading of $3.1 million, down 35.94% over the prior year.
  • Other Non-Current Assets was $881000.0 for Q3 2025 at Atara Biotherapeutics, down from $927000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $7.2 million in Q2 2022 and bottomed at $881000.0 in Q3 2025.
  • Average Other Non-Current Assets over 4 years is $4.3 million, with a median of $3.7 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets soared 211.08% in 2023, then crashed 74.31% in 2025.
  • Year by year, Other Non-Current Assets stood at $7.0 million in 2022, then crashed by 30.98% to $4.8 million in 2023, then tumbled by 35.94% to $3.1 million in 2024, then crashed by 71.61% to $881000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for ATRA at $881000.0 in Q3 2025, $927000.0 in Q2 2025, and $2.8 million in Q1 2025.